Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 132.49 -0.54 -0.41% 19.51%
Acadia Pharmaceuticals 21.18 -0.31 -1.44% -59.91%
Acorda Therapeutics 1.86 -0.06 -3.13% -75.53%
Adamas Pharmaceuticals 8.22 0.06 0.74% 91.16%
Aerie Pharmaceuticals 6.73 -0.38 -5.34% -59.96%
Aptinyx Inc 2.86 0.04 1.42% -28.86%
BioCryst Pharmaceuticals 13.78 -0.20 -1.43% 49.62%
Flexion Therapeutics 9.12 -0.02 -0.22% -17.76%
GlaxoSmithKline 1,644.80 8.20 0.50% 19.17%
Glaxosmithkline 45.10 0.22 0.49% 19.38%
GW Pharmaceuticals 218.96 0 0% 108.53%
Heron Therapeutics 8.38 -0.15 -1.76% -52.68%
Intra Cellular Therapies 42.66 3.79 9.75% 28.03%
Merck & Co 79.98 -0.77 -0.95% -1.23%
Marinus Pharmaceuticals 10.28 -0.28 -2.65% -23.91%
Neurocrine Biosciences 75.10 2.30 3.16% -35.76%
Novartis 79.78 -1.61 -1.98% -7.16%
Omeros 5.30 -0.05 -0.93% -73.06%
Prothena 35.23 -0.20 -0.56% 158.85%
Revance Therapeutics 13.43 -0.60 -4.28% -53.03%
Teva Pharmaceutical Industries Ltd 2,793.00 49.00 1.79% -31.54%
UCB 91.24 -0.16 -0.18% 4.18%
Zogenix 25.98 -0.02 -0.08% 34.61%

Indexes Price Day Year
NASDAQ 13769 -385.10 -2.72% 1.67%
US2000 1988 -36.12 -1.78% -8.34%

Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in drug discovery, development and commercialization to deliver medicines for patients, caregivers, and society. The Company’s portfolio product GOCOVRI (amantadine) extended release capsules is used for the treatment of dyskinesia in patients with Parkinson’s disease. Its OSMOLEX ER (amantadine) extended-release tablets is used for the treatment for Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients. Its ADS-5102 is in development for the treatment of walking impairment in patients with multiple sclerosis (MSW). Its product candidate ADS-4101 (lacosamide) modified release capsules is in development for the treatment of partial onset seizures in patients with epilepsy. Its Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules are used for the treatment of dementia of an Alzheimer’s type.